Showing 2001-2010 of 2105 results for "".
- Potential Redefinition of “Unresponsive” for People in Hospital With Brain Injurieshttps://practicalneurology.com/news/potential-redefinition-of-unresponsive-for-people-in-hospital-with-brain-injuries/2468943/The inability to follow a simple command, such as “move your hand” has been termed unresponsive and thought to prognosticate poor neurologic outcomes for those with brain injury. It has not been possible to elucidate whether this status arises from sensory, motor, or cognitive deficit
- OnabotulinumtoxinA Approved for Treatment of Children with Upper Limb Spasticityhttps://practicalneurology.com/news/onabotulinumtoxina-approved-for-treatment-of-children-with-upper-limb-spasticity/2468936/The Food and Drug Administration (FDA) has approved a new indication for onabotulinumtoxinA (Botox; Allergan, Madison, NJ)—treatment of upper limb spasticity in children, age 2 to 17 years. The decision came after a 6-month priority review, which istypically granted to therapies with potent
- Phase 2 Study of Potential Acute Ischemic Stroke Treatment Planned for 2019https://practicalneurology.com/news/phase-2-study-of-potential-acute-ischemic-stroke-treatment-planned-for-2019/2468930/A phase 2 proof-of-concept study will begin in the US later this year for LT3001 (Lumosa Therapeutics, Taipei, Taiwan), a novel therapy for treating acute ischemic stroke (AIS). Enrollment of participants for the phase 2 study in Taiwan will begin in 2020. Full enrollment is expected to take 2 ye
- Funding Provided for Project to Involve People with Dementia in Researchhttps://practicalneurology.com/news/funding-provided-for-project-to-involve-people-with-dementia-in-research/2468929/LiveWell Dementia Specialists in Plantsville, CT has received $250,000 in funding for a 2-year project to engage people with dementia as research partners. The first of its kind, the Empowering Partnerships project aims to enhance research by developing a network of people with dementia, family c
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e
- Novel Therapy for Alzheimer’s Disease Receives NIA Supporthttps://practicalneurology.com/news/novel-therapy-for-alzheimers-disease-receives-nia-support/2468907/The National Institute on Aging (NIA) has provided a 4-year grant for a phase 2 study of T3D-959 (T3D Therapeutics, Research Triangle Park, NC), a novel, metabolic-focused treatment for Alzheimer’s disease (AD). The PIONEER study, which will begin patient dosing in ear
- Zolgensma—Gene Replacement Therapy—for Treatment of Spinal Muscular Atrophyhttps://practicalneurology.com/news/zolgensmagene-replacement-therapyfor-treatment-of-spinal-muscular-atrophy/2468902/Results from multiple trials of SMN1gene-replacement therapy (Zolgensma; Avexis, Bannockburn, IL) show promise for single-dose treatment of spinal muscular atrophy (SMA). In the STRIVE phase 3 study for treatment of spinal muscular atrophy, 22 infants under age 6 months, diag
- Humanized Antibody Targets Tau Protein in Alzheimer's Diseasehttps://practicalneurology.com/news/humanized-antibody-targets-tau-protein-in-alzheimers-disease/2468881/A Harvard Medical School study demonstrates that a humanized monoclonal antibody (TBL-100; TAU BIOLOGIC Corporation, New York, NY) targets C-terminally truncated tau (tauC3) for the treatment of Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP).
- Nusinersen Efficacy for Later-Onset Spinal Muscular Atrophy Types II and IIIhttps://practicalneurology.com/news/nusinersen-efficacy-for-later-onset-spinal-muscular-atrophy-types-ii-and-iii/2468883/April 24, 2019—Children with later-onset spinal muscular atrophy (SMA) types II and III treated with nusinersen (Spinraza; Biogen, Cambridge MA) had motor function improvement and disease stabilization over a 3-year period. Of the children with SMA II, 78% (7 of 9) had clinically meaningful
- Analysis of Cladribine Tablets Clinical Trials Continues to Support Safety and Efficacyhttps://practicalneurology.com/news/analysis-of-cladribine-tablets-clinical-trials-continues-to-support-safety-and-efficacy/2468807/In the 2-year CLARITY trial (NCT00213135), 47% of patients treated with cladribine tablets (CT) (EMD Serono; Rockland, MA) achieved no evidence of disease activity (NEDA) compared with 17% of patients treated with placebo (P <